Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150398 | 0.84 | TSHR (0.56) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13287394 | 0.82 | GRIN2D (0.65) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8061377 | 0.81 | GRIN1 (0.71) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3190483 | 0.77 | GRIN1 (0.48) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL733849 | 0.77 | GRIN1 (0.48) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1073445 | 0.77 | TSHR (0.50) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| Dimethylamine SCHEMBL4774387 | 0.75 | GRIN1 (0.50) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4385378 | 0.75 | TSHR (0.53) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6868049 | 0.75 | GRIN2D (0.52) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| Bromide SCHEMBL4732099 | 0.75 | GRIN1 (0.46) | TSHRGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011125062-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2011-10-13 | — | — | WO | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | PNMT, PSEN2, CHRNA5 | TSHR 3555/4885GRIN2D 68/4885GRIN3B 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.